Wellgistics Health, Inc. (WGRX)

NASDAQ: WGRX · Real-Time Price · USD

0.6990

-0.0080 (-1.13%)

At close: Aug 13, 2025, 4:00 PM

0.6800

-0.0190 (-2.72%)

After-hours: Aug 13, 2025, 5:05 PM EDT

ASLAN Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	28.99	18.13	-	-
Cost of Revenue	26.53	16.36	-	-
Gross Profit	2.46	1.77	-	-
Selling, General & Admin	37.96	6.8	2.88	0.02
Operating Expenses	39.87	7.91	2.88	0.02
Operating Income	-37.41	-6.15	-2.88	-0.02
Interest Expense	-1.92	-0.83	-0.02	-
Other Non Operating Income (Expenses)	0.13	0.12	-	-
Pretax Income	-39.2	-6.86	-2.9	-0.02
Net Income	-39.2	-6.86	-2.9	-0.02
Net Income to Common	-39.2	-6.86	-2.9	-0.02
Shares Outstanding (Basic)	49	47	45	-
Shares Outstanding (Diluted)	49	47	45	-
Shares Change (YoY)	-	5.66%	-	-
EPS (Basic)	-0.80	-0.15	-0.06	-
EPS (Diluted)	-0.80	-0.15	-0.06	-
Gross Margin	8.48%	9.75%	-	-
Operating Margin	-129.05%	-33.90%	-	-
Profit Margin	-135.22%	-37.82%	-	-
EBITDA	-	-5.03	-	-
EBITDA Margin	-	-27.75%	-	-
D&A For EBITDA	-	1.11	-	-
EBIT	-37.41	-6.15	-2.88	-0.02
EBIT Margin	-129.05%	-33.90%	-	-

Updated Dec 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q